{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:25:08Z","timestamp":1784366708622,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T00:00:00Z","timestamp":1607126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The effects of direct-acting antivirals (DAAs) on survival and recurrence rates after curative hepatocellular carcinoma (HCC) treatment in patients with hepatitis C virus (HCV) infection remain controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, multicenter study involved Child\u2013Pugh class A patients within the Milan criteria who had a first diagnosis of HCC and survived 6\u00a0months or longer after undergoing hepatectomy or radiofrequency ablation (RFA). The DAA-treated group (DAA group) included 56 patients, and the DAA-untreated group (untreated group) included 261 patients. The study was conducted using the propensity score-matched (1:2) DAA group and untreated group, 56 and 112 patients, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The survival rate at 48\u00a0months in the DAA group and the untreated group was 91.0% and 68.7%, respectively, showing significantly better survival in the DAA group (HR: 0.33; 95% CI 0.13\u20130.84; <jats:italic>p<\/jats:italic>\u2009=\u20090.021). The recurrence rate at 48\u00a0months was 36.7% and 66.7%, respectively, showing a significantly lower recurrence rate in the DAA group (HR, 0.46; 95% CI 0.27\u20130.77; <jats:italic>p<\/jats:italic>\u2009=\u20090.003). The median albumin\u2013bilirubin (ALBI) score at 3\u00a0years post-HCC treatment was \u2212\u20092.84 in the DAA group and \u2212\u20092.34 in the untreated group. The ALBI score showed a significant improvement from baseline to 3\u00a0years post-HCC treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), whereas that in the untreated group showed a significant decline (<jats:italic>p<\/jats:italic>\u2009=\u20090.040).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>DAAs after HCC treatment prevents deterioration of hepatic functional reserve and significantly improves both recurrence and survival rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-020-01747-y","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T10:02:37Z","timestamp":1607162557000},"page":"90-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria"],"prefix":"10.1007","volume":"56","author":[{"given":"Hironori","family":"Ochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Azemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Tokumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Mashiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Michitaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8111-3266","authenticated-orcid":false,"given":"Kouji","family":"Joko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"1747_CR1","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/jmv.25533","volume":"91","author":"T Tada","year":"2019","unstructured":"Tada T, Toyoda H, Miyake N, et al. Natural history of liver-related disease in patient with chronic hepatitis C virus infection: An analysis using a Markov chain model. Nat J Med Virol. 2019;91:1837\u201344.","journal-title":"Nat J Med Virol"},{"key":"1747_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7326\/0003-4819-116-2-97","volume":"116","author":"RG Simonetti","year":"1992","unstructured":"Simonetti RG, Camm\u00e0 C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case control study. Ann Intern Med. 1992;116:97\u2013102.","journal-title":"Ann Intern Med"},{"key":"1747_CR3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","volume":"149","author":"F Negro","year":"2015","unstructured":"Negro F, Forton D, Crax\u00ec A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149:1345\u201360.","journal-title":"Gastroenterology"},{"key":"1747_CR4","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00535-018-1455-1","volume":"53","author":"K Tsuji","year":"2018","unstructured":"Tsuji K, Kurosaki M, Itakura J, et al. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018;53:1142\u201350.","journal-title":"J Gastroenterol"},{"key":"1747_CR5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649\u201359.","journal-title":"Gastroenterology"},{"key":"1747_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol. 2017;67:263\u201371.","journal-title":"J Hepatol"},{"key":"1747_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329\u201337.","journal-title":"Ann Intern Med"},{"key":"1747_CR8","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1245\/s10434-017-6008-y","volume":"24","author":"H Shinkawa","year":"2017","unstructured":"Shinkawa H, Hasegawa K, Arita J, et al. Impact of sustained virological response to interferon therapy on recurrence of hepatitis C virus-related hepatocellular carcinoma. Ann Surg Oncol. 2017;24:3196\u2013202.","journal-title":"Ann Surg Oncol"},{"key":"1747_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/hepr.12515","volume":"46","author":"K Joko","year":"2016","unstructured":"Joko K, Goto T, Watanabe H, et al. Effects of antiviral therapy C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group. Hepatol Res. 2016;46:251\u20138.","journal-title":"Hepatol Res"},{"key":"1747_CR10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s10620-011-1934-1","volume":"57","author":"H Miyatake","year":"2012","unstructured":"Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2012;57:1092\u2013101.","journal-title":"Dig Dis Sci"},{"key":"1747_CR11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1245\/s10434-011-1866-1","volume":"19","author":"Y Tanimoto","year":"2012","unstructured":"Tanimoto Y, Tashiro H, Aikata H, et al. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2012;19:418\u201325.","journal-title":"Ann Surg Oncol"},{"key":"1747_CR12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"F Conti","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727\u201333.","journal-title":"J Hepatol"},{"key":"1747_CR13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"M Reig","year":"2016","unstructured":"Reig M, Mari\u00f1o Z, Perell\u00f3 C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719\u201326.","journal-title":"J Hepatol"},{"issue":"13","key":"1747_CR14","doi-asserted-by":"crossref","first-page":"e0194704","DOI":"10.1371\/journal.pone.0194704","volume":"16","author":"T Mashiba","year":"2018","unstructured":"Mashiba T, Joko K, Kurosaki M, et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS ONE. 2018;16(13):e0194704.","journal-title":"PLoS ONE"},{"key":"1747_CR15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","volume":"156","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology. 2019;156:1683\u201392.","journal-title":"Gastroenterology"},{"key":"1747_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","volume":"71","author":"G Cabibbo","year":"2019","unstructured":"Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265\u201373.","journal-title":"J Hepatol"},{"key":"1747_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1872-034X.2007.00216.x","volume":"38","author":"M Makuuchi","year":"2008","unstructured":"Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38:37\u201351.","journal-title":"Hepatol Res"},{"key":"1747_CR18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"1747_CR19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology"},{"key":"1747_CR20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI Grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"key":"1747_CR21","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med"},{"key":"1747_CR22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"},{"key":"1747_CR23","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31:2963\u20139.","journal-title":"J Clin Oncol"},{"key":"1747_CR24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-017-0405-6","volume":"17","author":"IS Cho","year":"2017","unstructured":"Cho IS, Chae YR, Kim JH, et al. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study. BMC Med Res Methodol. 2017;17:126.","journal-title":"BMC Med Res Methodol"},{"key":"1747_CR25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"43","author":"U Dafni","year":"2011","unstructured":"Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;43:363\u201371.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1747_CR26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","volume":"252","author":"J Huang","year":"2010","unstructured":"Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903\u201312.","journal-title":"Ann Surg"},{"key":"1747_CR27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MCG.0000000000000133","volume":"49","author":"YH Lee","year":"2015","unstructured":"Lee YH, Hsu CY, Chu CW, et al. Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses. J Clin Gastroenterol. 2015;49:242\u20139.","journal-title":"J Clin Gastroenterol"},{"key":"1747_CR28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/hepr.12035","volume":"43","author":"K Imai","year":"2013","unstructured":"Imai K, Beppu T, Chikamoto A, et al. Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res. 2013;43:853\u201364.","journal-title":"Hepatol Res"},{"key":"1747_CR29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1245\/s10434-009-0407-7","volume":"16","author":"T Kamiyama","year":"2009","unstructured":"Kamiyama T, Nakanishi K, Yokoo H, et al. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol. 2009;16:1560\u201371.","journal-title":"Ann Surg Oncol"},{"key":"1747_CR30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/hpb.12311","volume":"16","author":"SY Lee","year":"2014","unstructured":"Lee SY, Konstantinidis IT, Eaton AA, et al. Predicting recurrence patterns after resection of hepatocellular cancer. HPB (Oxford). 2014;16:943\u201353.","journal-title":"HPB (Oxford)"},{"key":"1747_CR31","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1245\/s10434-014-3609-6","volume":"21","author":"JJ Lee","year":"2014","unstructured":"Lee JJ, Kim PT, Fischer S, et al. Impact of viral hepatitis on outcomes after liver resection for hepatocellular carcinoma: results from a North American center. Ann Surg Oncol. 2014;21:2708\u201316.","journal-title":"Ann Surg Oncol"},{"key":"1747_CR32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11605-016-3344-3","volume":"21","author":"K Sasaki","year":"2017","unstructured":"Sasaki K, Shindoh J, Nishioka Y, et al. Impact of viral etiology on postoperative de novo recurrence after hepatectomy for hepatocellular carcinoma in cirrhotic patients. J Gastrointest Surg. 2017;21:487\u201395.","journal-title":"J Gastrointest Surg"},{"key":"1747_CR33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.510250116","volume":"25","author":"T Kumada","year":"1997","unstructured":"Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87\u201392.","journal-title":"Hepatology"},{"key":"1747_CR34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","volume":"38","author":"H Imamura","year":"2003","unstructured":"Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200\u20137.","journal-title":"J Hepatol"},{"key":"1747_CR35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1872-034X.2011.00959.x","volume":"42","author":"M Sakae","year":"2012","unstructured":"Sakae M, Kubo S, Takemura S, et al. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2012;42:564\u201373.","journal-title":"Hepatol Res"},{"key":"1747_CR36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.13452","volume":"37","author":"S Bruno","year":"2017","unstructured":"Bruno S, Di Marco V, Iavarone M, et al. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int. 2017;37:1526\u201334.","journal-title":"Liver Int"},{"key":"1747_CR37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/1743-422X-7-375","volume":"7","author":"Y Nagao","year":"2010","unstructured":"Nagao Y, Sata M. Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Virol J. 2010;7:375.","journal-title":"Virol J"},{"key":"1747_CR38","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.5301\/ijbm.5000300","volume":"32","author":"BI Carr","year":"2017","unstructured":"Carr BI, Guerra V. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients. Int J Biol Mark. 2017;32:e391\u20136.","journal-title":"Int J Biol Mark"},{"key":"1747_CR39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/hepr.12999","volume":"48","author":"R Sugimoto","year":"2018","unstructured":"Sugimoto R, Iwasa M, Hara N, et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res. 2018;48:337\u201344.","journal-title":"Hepatol Res"},{"key":"1747_CR40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.surge.2017.07.003","volume":"16","author":"CC Chong","year":"2018","unstructured":"Chong CC, Chan AW, Wong J, et al. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early\/early stage of hepatocellular carcinoma. Surgeon. 2018;16:163\u201370.","journal-title":"Surgeon"},{"key":"1747_CR41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.hpb.2017.12.001","volume":"20","author":"CC Chong","year":"2018","unstructured":"Chong CC, Lee KF, Chu CM, et al. Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. HPB (Oxford). 2018;20:546\u201354.","journal-title":"HPB (Oxford)."},{"key":"1747_CR42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000494844","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Michitaka K, et al. Newly Proposed ALBI Grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer. 2019;8:312\u201325.","journal-title":"Liver Cancer"},{"key":"1747_CR43","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453\u201364.","journal-title":"Lancet"},{"key":"1747_CR44","doi-asserted-by":"crossref","first-page":"871401","DOI":"10.1155\/2012\/871401","volume":"2012","author":"T Himoto","year":"2012","unstructured":"Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol. 2012;2012:871401.","journal-title":"Clin Dev Immunol"},{"key":"1747_CR45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-133-8-200010170-00009","volume":"133","author":"SH Mehta","year":"2000","unstructured":"Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592\u20139.","journal-title":"Ann Intern Med"},{"key":"1747_CR46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/jhep.2002.31257","volume":"35","author":"RC Hilsabeck","year":"2002","unstructured":"Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440\u20136.","journal-title":"Hepatology"},{"key":"1747_CR47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, Jen CL, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469\u201377.","journal-title":"J Infect Dis"},{"key":"1747_CR48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/hepr.13278","volume":"49","author":"T Watanabe","year":"2019","unstructured":"Watanabe T, Tokumoto Y, Joko K, et al. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49:136\u201346.","journal-title":"Hepatol Res"},{"key":"1747_CR49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000367727","volume":"4","author":"M Kudo","year":"2015","unstructured":"Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4:39\u201350.","journal-title":"Liver Cancer"},{"key":"1747_CR50","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1245\/s10434-008-9846-9","volume":"15","author":"S Sumie","year":"2008","unstructured":"Sumie S, Kuromatsu R, Okuda K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375\u201382.","journal-title":"Ann Surg Oncol"},{"key":"1747_CR51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hepr.13254","volume":"49","author":"Y Kawamura","year":"2019","unstructured":"Kawamura Y, Ikeda K, Shindoh J, et al. No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection. Hepatol Res. 2019;49:164\u201376.","journal-title":"Hepatol Res"},{"key":"1747_CR52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/hepr.12838","volume":"47","author":"Y Kawamura","year":"2017","unstructured":"Kawamura Y, Ikeda K, Fujiyama S, et al. Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas. Hepatol Res. 2017;47:1008\u201320.","journal-title":"Hepatol Res"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01747-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-020-01747-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-020-01747-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T16:47:59Z","timestamp":1611247679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-020-01747-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,5]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1747"],"URL":"https:\/\/doi.org\/10.1007\/s00535-020-01747-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,5]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}